Review Article
Oncogenic Alternative Splicing Switches: Role in Cancer Progression and Prospects for Therapy
Table 2
Examples of ASO treatments in cancer cell lines.
| Gene | Function | Reference |
| SRA1, Steroid Receptor RNA Activator gene | Retention of intron 1 alters the reading frame and occurs in breast tumors with high progesterone receptor contents | [144] | Mcl-1, myeloid cell leukemia-1 | Antiapoptotic protein of the Bcl-2 family overexpressed in many tumors | [145] | erbB-2, Her-2 receptor | Skipping of exon 19 produces a dominant-negative protein isoform | [146] | IG20, death-domain adaptor protein Insulinoma-Glucagonoma 20 | Antiapoptotic alternative splicing isoform expressed in gliomas | [147] | CASP9, caspase9 | Two isoforms generated by alternative splicing: a proapoptotic and a prosurvival variant | [148] | PKM, pyruvate kinase M | The PKM2 isoform is crucial for aerobic glycolysis (the Warburg effect) and tumor growth | [149, 150] | hTERT, telomerase | Alternative splicing generates many nonfunctional products. ASOs treatment increases nonfunctional telomerase products in cancer cells | [151] |
|
|